FDA approves UCB’s Cimzia in plaque psoriasis
Cimzia, dermatology, immuno-dermatology, psoriasis, skin condition, UCB
0 Comment
The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis